How many insider trades does FilingIQ track for DSGN?

FilingIQ tracks 60 Form 4 insider transactions for DSGN (Design Therapeutics, Inc.), covering filings from Mar 30, 2021 onwards. 2 of those were filed in the last 90 days.

Are DSGN insiders net buyers or net sellers?

Across the full Form 4 history for DSGN, 28 transactions (47%) were open-market purchases and 8 (13%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does DSGN insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is DSGN in?

Design Therapeutics, Inc. (DSGN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $649.41M.

DSGN insider trading

NasdaqGS Healthcare

Design Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

47% / 13%

Market cap

$649.41M

About Design Therapeutics, Inc.

Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. The company was incorporated in 2017 and is headquartered in Carlsbad, California.

Company website: www.designtx.com

DSGN insider activity at a glance

FilingIQ has scored 60 insider transactions for DSGN since Mar 30, 2021. The most recent filing in our index is dated Mar 31, 2026.

Across the full history, 28 open-market purchases and 8 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on DSGN insider trades is 50.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live DSGN trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding DSGN

Logos Global Management LP

$16.86M · 1.4% of AUM

Frequently asked

How many insider trades does FilingIQ track for DSGN?: FilingIQ tracks 60 Form 4 insider transactions for DSGN (Design Therapeutics, Inc.), covering filings from Mar 30, 2021 onwards. 2 of those were filed in the last 90 days.
Are DSGN insiders net buyers or net sellers?: Across the full Form 4 history for DSGN, 28 transactions (47%) were open-market purchases and 8 (13%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does DSGN insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is DSGN in?: Design Therapeutics, Inc. (DSGN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $649.41M.

Methodology & sources

Every DSGN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.